Here are four takeaways:
1. Four new patents were issued for the company’s amniotic membrane allograft product lines and eight for the company’s CollaFix technology platform.
2. Three of the 12 patents were issued to MiMedx since Nov. 1, 2015.
3. MiMedx is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants.
4. It develops products and therapies for the wound care, surgical, orthopedic, spine, sports medicine, ophthalmic and dental markets.
More articles on devices:
5 key notes on minimally invasive SI joint fusion implant survivorship
5 key trends driving the spine & orthopedic device market development today
K2M, SeaSpine, Blue Belt & more: 18 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
